MDVN Medivation, Inc. (MM)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

(Rule 14d-101)

Solicitation/Recommendation Statement

Under Section 14(d)(4) of the Securities Exchange Act of 1934

MEDIVATION, INC.

(Name of Subject Company)

MEDIVATION, INC.

(Name of Person Filing Statement)

Common Stock, $0.01 par value per share, including associated preferred stock purchase rights

(Title of Class of Securities)

58501N101

(CUSIP Number of Class of Securities)

Andrew Powell

General Counsel and Corporate Secretary

Medivation, Inc.

525 Market Street, 36th Floor

San Francisco, California 94105

(415) 543-3470

(Name, Address and Telephone Number of Person Authorized to Receive Notices and

Communications on Behalf of the Person Filing Statement)

With copies to:

On August 22, 2016, Medivation, Inc. (“Medivation”) and Pfizer Inc. (“Pfizer”) issued a joint press release announcing the execution of an Agreement and Plan of Merger (the “Merger Agreement”). Pursuant to the Merger Agreement, Montreal, Inc., a wholly owned subsidiary of Pfizer (“Purchaser”), will commence a tender offer (the “Offer”) to purchase all of the issued and outstanding shares of Medivation common stock, including the associated preferred stock purchase rights issued under the Rights Agreement, dated December 4, 2006, as amended, between Medivation and American Stock Transfer & Trust Company, for $81.50 per share in cash. If successful, the Offer will be followed by a merger of Purchaser with and into Medivation (the “Merger”).

This Schedule 14D-9 filing consists of the following documents relating to the proposed Offer and Merger:

Grafico Azioni Medivation, Inc. (MM) (NASDAQ:MDVN)
Storico
Da Gen 2025 a Feb 2025

Grafico Azioni Medivation, Inc. (MM) (NASDAQ:MDVN)
Storico
Da Feb 2024 a Feb 2025